In short
KITE-753 is an investigational cell therapy being studied in a Phase 3 clinical trial for people with large B-cell lymphoma that has returned after treatment or not responded to treatment. The trial compares KITE-753 against axicabtagene ciloleucel, an existing CAR T-cell therapy, in 550 participants. The study is authorised and currently recruiting in the European Union.
Key points
- KITE-753 is an investigational cell therapy for large B-cell lymphoma
- Being tested in a Phase 3 clinical trial
- The trial compares KITE-753 against axicabtagene ciloleucel, an approved CAR T-cell therapy
- 550 participants with relapsed or refractory large B-cell lymphoma
- The trial is authorised in the European Union
- The main goal is to measure efficacy compared to the existing therapy
What is KITE-753?
KITE-753 is an investigational substance being studied in the treatment of large B-cell lymphoma, a type of blood cancer affecting white blood cells called B lymphocytes. The trial record does not specify the exact class of substance KITE-753 belongs to, but it is being compared against axicabtagene ciloleucel, a chimeric antigen receptor (CAR) T-cell therapy. KITE-753 is not yet authorised as a medicine; it remains under investigation in clinical research.
How does KITE-753 work?
The available trial register does not describe the mechanism of action of KITE-753 in detail. The study is designed to evaluate the efficacy of KITE-753 compared with axicabtagene ciloleucel in people with relapsed or refractory large B-cell lymphoma. Because the trial compares KITE-753 against a CAR T-cell therapy, KITE-753 is being assessed in the same clinical setting, but the register does not state its mechanism.
Which conditions is KITE-753 being studied for?
- Relapsed large B-cell lymphoma — a form of aggressive blood cancer that has returned after previous treatment.
- Refractory large B-cell lymphoma — large B-cell lymphoma that did not respond to earlier treatment.
How is KITE-753 given?
The trial register does not state the pharmaceutical form or route of administration for KITE-753. The comparator, axicabtagene ciloleucel, is given as an intravenous infusion, but no information is provided on how KITE-753 itself is administered in this study.
What do the clinical trials show?
One clinical trial of KITE-753 is registered in the EU Clinical Trials Information System. It is a Phase 3 study with a planned enrolment of 550 participants. The trial is authorised, meaning it has received approval to proceed in the European Union. The study compares KITE-753 against axicabtagene ciloleucel to evaluate efficacy in people with large B-cell lymphoma that has returned after treatment or not responded to treatment. The trial record does not report results; the study is ongoing.